Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors

Future Oncology

Volumn 9, Issue 7, 2013, Pages 977-990

  Chandramohan, Vidyalakshmi ^a   Mitchell, Duane A ^a   Johnson, Laura A ^a,b   Sampson, John H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

brain tumor; dendritic cell; immunotherapy; monoclonal antibody; T cell

Indexed keywords

BACTERIAL TOXIN; BEVACIZUMAB; CETUXIMAB; CHIMERIC ANTIBODY; DENDRITIC CELL VACCINE; EXOTOXIN; IMC 3G 3; IMMUNOTOXIN; IRINOTECAN; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEURADIAB; NIMOTUZUMAB; OLARATUMAB; PLANT TOXIN; PLATELET DERIVED GROWTH FACTOR; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DELETION MUTANT; EXTERNAL BEAM RADIOTHERAPY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; LIGAND BINDING; LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSEUDOMONAS AERUGINOSA; RADIOIMMUNOTHERAPY; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; DENDRITIC CELLS; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; RADIOIMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 84880244272     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.47     Document Type: Review

References (118)

1. Bailey P, Cushing HA. A classification of tumours of the glioma group on a histogenetic basis with a correlated study of prognosis. Br. J. Surg. 14(55), 554-555 (1926).
2. Louis DN, Gusella JF. A tiger behind many doors: Multiple genetic pathways to malignant glioma. Trends Genet. 11(10), 412-415 (1995).
3. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459-466 (2009).
4. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
5. Pachter JS, De Vries HE, Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J. Neuropathol. Exp. Neurol. 62(6), 593-604 (2003).
6. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol. Today 15(5), 218-224 (1994).
7. Lampson LA, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J. Immunol. 136(11), 4054-4062 (1986).
8. Tambur AR. Transplantation immunology and the central nervous system. Neurol. Res. 26(3), 243-255 (2004).
9. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28(2), 254-260 (1991).
10. Perry VH, Anthony DC, Bolton SJ, Brown HC. The blood-brain barrier and the inflammatory response. Mol. Med. Today 3(8), 335-341 (1997).
11. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells trafffrom brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J. Leukoc. Biol. 80(4), 797-801 (2006).
12. Calzascia T, Masson F, Di Berardino-Besson W et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22(2), 175-184 (2005).
13. Serot JM, Foliguet B, Bene MC, Faure GC. Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport 8(8), 1995-1998 (1997).
14. Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 17(1), 6-10 (2010).
15. Freund J. Accumulation of antibodies in the central nervous system. J. Exp. Med. 51(6), 889-902 (1930).
16. Bullard DE, Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. J. Neurosurg. 63(1), 2-16 (1985).
17. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359(6398), 845-848 (1992).
18. Raizer JJ, Grimm S, Chamberlain MC et al. A Phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116(22), 5297-5305 (2010).
19. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70(10), 779-787 (2008).
20. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
21. Gutin PH, Iwamoto FM, Beal K et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 156-163 (2009).
22. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11(1), 69-82 (2007).
23. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
24. Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
25. Arita N, Hayakawa T, Izumoto S et al. Epidermal growth factor receptor in human glioma. J. Neurosurg. 70(6), 916-919 (1989).
26. Friedlander E, Barok M, Szollosi J, Vereb G. ErbB-directed immunotherapy: Antibodies in current practice and promising new agents. Immunol. Lett. 116(2), 126-140 (2008).
27. Hasselbalch B, Lassen U, Hansen S et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A Phase II trial. Neuro Oncol. 12(5), 508-516 (2010).
28. Neyns B, Sadones J, Joosens E et al. Stratified Phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol. 20(9), 1596-1603 (2009).
29. Cloughesy TF, Prados MD, Wen PY et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol. 26(91S), Abstract 2010b (2008).
30. Bode U, Buchen M, Warmuth-Metz M et al. Final report of a Phase II trial of nimotuzumab in the treatment of refractory and relapsed highgrade gliomas in children and adolescents. J. Clin. Oncol. 24(Suppl. 18), 1522 (2006).
31. Ramos TC, Figueredo J, Catala M et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a Phase I/II trial. Cancer Biol. Ther. 5(4), 375-379 (2006).
32. Humphrey PA, Wong AJ, Vogelstein B et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl Acad. Sci. USA 87(11), 4207-4211 (1990).
33. Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl Acad. Sci. USA 97(13), 7503-7508 (2000).
34. Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. 11(17), 6390-6399 (2005).
35. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1), 98-110 (2010).
36. Loizos N, Xu Y, Huber J et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target. Mol. Cancer Ther. 4(3), 369-379 (2005).
37. Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43(6), 2796-2805 (1983).
38. Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24(1), 115-122 (2006).
39. Riva P, Franceschi G, Frattarelli M et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - Phase I and II study. Acta Oncol. 38(3), 351-359 (1999).
40. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur. J. Nucl. Med. 27(5), 601-609 (2000).
41. Petronzelli F, Pelliccia A, Anastasi AM et al. Improved tumor targeting by combined use of two antitenascin antibodies. Clin. Cancer Res. 11(19 Pt 2), 7137s-7145s (2005).
42. Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20(5), 1389-1397 (2002).
43. Casaco A, Lopez G, Garcia I et al. Phase I single-dose study of intracavitary-administered nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 7(3), 333-339 (2008).
44. Yang W, Wu G, Barth RF et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3), 883-891 (2008).
45. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, Mclendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. Glia 15(3), 244-256 (1995).
46. Cokgor I, Akabani G, Friedman HS et al Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab́)(2): A case study. Cancer 91(9), 1809-1813 (2001).
47. Recht L, Torres CO, Smith TW, Raso V, Griffin TW. Transferrin receptor in normal and neoplastic brain tissue: Implications for brain-tumor immunotherapy. J. Neurosurg. 72(6), 941-945 (1990).
48. Recht LD, Griffin TW, Raso V, Salimi AR. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro. Cancer Res. 50(20), 6696-6700 (1990).
49. Martell LA, Agrawal A, Ross DA, Muraszko KM. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res. 53(6), 1348-1353 (1993).
50. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. 80(3), 520-526 (1994).
51. Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin. Cancer Res. 1(8), 859-864 (1995).
52. Archer GE, Sampson JH, Lorimer IA et al. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin. Cancer Res. 5(9), 2646-2652 (1999).
53. Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin. Cancer Res. 6(7), 2835-2843 (2000).
54. Kuan CT, Wakiya K, Dowell JM et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin. Cancer Res. 12(7 Pt 1), 1970-1982 (2006).
55. Kuan CT, Wakiya K, Keir ST et al. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int. J. Cancer 129(1), N (2011).
56. Hjortland GO, Garman-Vik SS, Juell S et al. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J. Neurosurg. 100(2), 320-327 (2004).
57. Ayriss J, Reisfeld R, Kuan C-T, Keir S, Pastan I, Bigner DD. Mel-14 and 9.2.27 immunotoxins: Promising therapeutics for pediatric glioma. Presented at: 2011 Pediatric Neuro-Oncology Basic and Translational Research Conference. New Orleans, LA, USA, 19-20 May 2011.
58. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
59. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006).
60. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
61. Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19(3), 620-626 (2011).
62. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
63. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90(2), 720-724 (1993).
64. Chekmasova AA, Rao TD, Nikhamin Y et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16(14), 3594-3606 (2010).
65. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116(19), 3875-3886 (2010).
66. Zhao Y, Wang QJ, Yang S et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183(9), 5563-5574 (2009).
67. Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2), 474-485 (2010).
68. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64(24), 9160-9166 (2004).
69. Morgan RA, Johnson LA, Davis J et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23(10), 1043-1053 (2012).
70. Chow KK, Naik S, Kakarla S et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21(3), 629-637 (2012).
71. Brown CE, Starr R, Aguilar B et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells. Clin. Cancer Res. 18(8), 2199-2209 (2012).
72. Kong S, Sengupta S, Tyler B et al. Suppression of human glioma xenografts with second-generation IL13Rspecific chimeric antigen receptor-modified T cells. Clin. Cancer Res. 18(21), 5949-5960 (2012).
73. Chinnasamy D, Yu Z, Theoret MR et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120(11), 3953-3968 (2010).
74. Pule MA, Savoldo B, Myers GD et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008).
75. Lamers CH, Gratama JW, Pouw NM et al. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: Implications for loss of transgene expression. Hum. Gene Ther. 16(12), 1452-1462 (2005).
76. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
77. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
78. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011).
79. Till BG, Jensen MC, Wang J et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261-2271 (2008).
80. Yaghoubi SS, Jensen MC, Satyamurthy N et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 6(1), 53-58 (2009).
81. Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PloS One 5(3), e9750 (2010).
82. Ohno M, Natsume A, Ichiro Iwami K et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 101(12), 2518-2524 (2010).
83. Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front. Biosci. 12, 4050-4060 (2007).
84. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007).
85. Fecci PE, Mitchell DA, Archer GE et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J. Neurooncol. 64(1-2), 161-176 (2003).
86. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012).
87. Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J. Neurosurg. 55(1), 32-42 (1981).
88. Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27, 452-459 (2004).
89. Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005).
90. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
91. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61(3), 842-847 (2001).
92. van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S. Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19(4), 694-712 (2009).
93. De Vleeschouwer S, Fieuws S, Rutkowski S et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin. Cancer Res. 14(10), 3098-3104 (2008).
94. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64(14), 4973-4979 (2004).
95. Phuphanich S, Wheeler CJ, Rudnick JD et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol. Immunother. 62(1), 125-135 (2013).
96. Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011).
97. Iwami K, Shimato S, Ohno M et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A.*24/A.*02 allele. Cytotherapy 14(6), 733-742 (2012).
98. Sampson JH, Archer GE, Mitchell DA et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther. 8(10), 2773-2779 (2009).
99. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther. 9(8), 1087-1098 (2009).
100. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
101. Yamanaka R, Itoh K. Peptide-based immunotherapeutic approaches to glioma: A review. Expert Opin. Biol. Ther. 7(5), 645-649 (2007).
102. Okada H, Kalinski P, Ueda R et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with a-type 1 polarized dendritic cells and polyinosinic- polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011).
103. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: A meta-analysis. J. Natl Compr. Canc. Netw. 9(4), 403-407 (2011).
104. Castiello L, Sabatino M, Jin P et al. Monocyte-derived DC maturation strategies and related pathways: A transcriptional view. Cancer Immunol. Immunother. 60(4), 457-466 (2011).
105. Schmidt SV, Nino-Castro AC, Schultze JL. Regulatory dendritic cells: There is more than just immune activation. Front. Immunol. 3, 274 (2012).
106. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006).
107. Mitchell DA, Cui X, Schmittling RJ et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 118(11), 3003-3012 (2011).
108. Cho D-Y, Yang W-K, Lee H-C et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: A Phase II clinical trial. World Neurosurg. 77(5-6), 736-744 (2012).
109. Copur MS, Obermiller A. Ipilimumab plus dacarbazine in melanoma. N. Engl. J. Med. 365(13), 1256-1257; author reply 1257-1258 (2011).
110. Hodi FS, O'Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
111. Hwu P. Treating cancer by targeting the immune system. N. Engl. J. Med. 363(8), 779-781 (2010).
112. Fecci PE, Ochiai H, Mitchell DA et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13(7), 2158-2167 (2007).
113. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
114. Ribas A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366(26), 2517-2519 (2012).
115. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
116. Wainwright DA, Balyasnikova IV, Chang AL et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18(22), 6110-6121 (2012).
117. Hussain SF, Kong LY, Jordan J et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67(20), 9630-9636 (2007).
118. Franks HA, Wang Q, Patel PM. New anticancer immunotherapies. Anticancer Res. 32(7), 2439-2453 (2012).